The Next Generation of Weight-Loss Drugs Is Here. Will Health Insurers Cover Them?

The treatment of obesity has changed dramatically over the past few years. Medications once viewed primarily as tools for weight management are now recognized as important therapies for chronic diseases linked to obesity, including type 2 diabetes, cardiovascular disease, obstructive sleep apnea, fatty liver disease, and other serious health conditions. As the science advances, pharmaceutical companies continue to develop medications that are more effective and easier for patients to take.

The latest examples include Foundayo (orforglipron), Eli Lilly’s newly approved oral GLP-1 medication, and retatrutide, an investigational drug that has produced remarkable results in clinical trials and may represent the next major breakthrough in obesity treatment. Unfortunately, history suggests that medical innovation is only part of the story. As new weight-loss drugs reach the market, another question quickly follows: Will health insurance companies actually cover them?

At Gianelli & Morris, we have seen insurers repeatedly deny coverage for medically necessary treatments using evolving justifications. The experience with GLP-1 medications demonstrates how coverage disputes often change over time—and, in some cases, how those denials can give rise to insurance bad faith claims.

Obesity Is a Serious Chronic Disease Affecting Millions of Americans

The growing interest in GLP-1 medications reflects the enormous public health impact of obesity. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately two out of every five American adults have obesity, while more than seven out of every ten adults are overweight or have obesity. Childhood obesity remains a major public health concern as well.

These statistics matter because excess weight is associated with numerous chronic medical conditions, including:

• Type 2 diabetes
• High blood pressure
• Coronary artery disease
• Stroke
• Obstructive sleep apnea
• Osteoarthritis
• Metabolic dysfunction-associated steatotic liver disease (MASLD)
• Certain forms of cancer

For many patients, GLP-1 medications are not simply helping them lose weight. They are prescribed to reduce serious health risks, improve quality of life, and help manage chronic diseases that become increasingly difficult and expensive to treat if left unchecked.

Foundayo Offers a More Convenient Option

One of the biggest recent developments is the FDA approval of Foundayo (orforglipron), Eli Lilly’s first oral GLP-1 medication approved for weight management. Unlike injectable medications such as Zepbound or Wegovy, Foundayo is taken as a once-daily pill. Its convenience extends beyond eliminating injections. Patients can take the medication at any time of day, with or without food, and without the timing or water restrictions that have complicated the use of some earlier oral GLP-1 medications. For many patients who have been reluctant to begin injectable therapy, these advantages may make Foundayo an attractive alternative.

The approval of another effective obesity medication is also likely to increase demand for insurance coverage, raising new questions about how health plans will respond as more patients seek access to these therapies.

Retatrutide May Represent the Next Breakthrough

Even as Foundayo enters the market, researchers are already looking ahead to the next generation of obesity treatment. Retatrutide is an investigational medication that works differently from currently approved GLP-1 drugs. Rather than targeting one or two hormone receptors, retatrutide activates three separate pathways involving GLP-1, GIP, and glucagon receptors. Early clinical trials have produced extraordinary weight-loss results, generating significant excitement within the medical community.

However, retatrutide has not yet received FDA approval. At present, it remains investigational and is generally available only through clinical trials or limited expanded-access programs. Because of its current status, many insurers would likely deny coverage on the ground that the medication is experimental or investigational. At this stage, those denials may be consistent with the language contained in many health insurance policies. However, that legal analysis changes once a medication receives FDA approval.

From “Experimental” to “Medical Necessity”

One of the most interesting trends involving GLP-1 medications is how insurers’ reasons for denying coverage have evolved. Before a medication receives FDA approval, insurers often rely on policy provisions excluding experimental or investigational treatments. After approval, those arguments may not entirely disappear, but they become less frequent. Instead, health plans often shift their focus to medical necessity. They may require patients to satisfy detailed prior authorization criteria, document unsuccessful attempts with other therapies, meet specific body mass index thresholds, or demonstrate obesity-related medical conditions before coverage will be approved.

These disputes have become increasingly common in California. A review of California Department of Managed Health Care (DMHC) Independent Medical Review (IMR) decisions involving Zepbound during 2026 reveals a striking pattern. Independent reviewers overturned 77 health plan denials while upholding only four. Nearly all of those disputes involved questions of medical necessity rather than whether the medication was experimental.

That statistic does not mean every insurer acted in bad faith. Health plans have the right to evaluate whether a requested treatment satisfies the terms of the policy and applicable medical necessity standards. However, it does demonstrate that insurers and independent reviewing physicians frequently reach very different conclusions regarding whether patients should receive these medications.

For consumers, the message is simple: an initial denial should not necessarily be viewed as the final answer.

Why Insurers Are Tightening Coverage

When GLP-1 medications first entered the market, many health plans covered them with relatively modest restrictions. As demand exploded and treatment costs increased, however, insurers and employer-sponsored health plans began reevaluating their coverage policies. Some employers eliminated coverage for weight-loss medications altogether. Others imposed stricter prior authorization requirements or added new exclusions limiting who could receive the drugs.

State health plans have taken similar actions. The North Carolina State Health Plan announced it would discontinue coverage of GLP-1 medications for weight loss because of escalating costs. Blue Cross Blue Shield of Michigan also announced significant changes to its coverage policies. In California, Governor Gavin Newsom’s proposed budget previously included eliminating Medi-Cal coverage for certain weight-loss medications as part of broader efforts to address the state’s budget deficit, although that proposal generated significant opposition from physicians and patient advocates. These developments illustrate an uncomfortable reality: medical advances often outpace insurance coverage.

When Medical Necessity Becomes an Insurance Bad Faith Issue

A disagreement over medical necessity does not automatically create an insurance bad faith claim. Health insurers are permitted to evaluate claims, review medical evidence, and apply reasonable coverage criteria. Problems arise, however, when those reviews are conducted unfairly or unreasonably. For example, disputes may arise when a health plan:

• Relies on outdated medical policies that no longer reflect current scientific evidence.
• Ignores compelling recommendations from the patient’s treating physicians.
• Applies blanket exclusions without conducting an individualized review.
• Mischaracterizes FDA-approved medications as experimental or investigational.
• Applies medical necessity criteria inconsistently.
• Unreasonably delays approval despite overwhelming supporting medical evidence.

California law requires insurers to thoroughly and fairly investigate claims while giving equal consideration to the interests of their insureds. When an insurer fails to do so, the consequences may extend far beyond the denial of a prescription.

The Stakes Are About More Than Weight Loss

Obesity treatment is no longer viewed simply as a matter of helping patients lose weight. For many individuals, these medications may reduce the risk of diabetes, heart disease, kidney disease, liver disease, and other chronic conditions that significantly affect both quality of life and long-term health care costs. Delaying or denying medically appropriate treatment can have serious consequences. A patient who cannot obtain effective obesity treatment today may later require hospitalization, surgery, dialysis, or lifelong treatment for preventable complications. That is one reason disputes involving GLP-1 medications have become increasingly significant.

How Gianelli & Morris Helps California Policyholders

As innovative therapies continue to reshape the treatment of obesity, insurance coverage disputes are likely to become more—not less—common. Today’s disputes often involve medications like Zepbound and Foundayo. Tomorrow’s disputes may center on promising therapies such as retatrutide once FDA approval is obtained.

At Gianelli & Morris, we represent policyholders throughout California whose health plans have wrongfully denied medically necessary care. Our attorneys understand the complex medical policies, utilization review standards, and insurance practices that often determine whether a claim is approved or denied.

Whether a denial is based on allegations that a treatment is experimental, disputes over medical necessity, or reliance on outdated coverage policies, we help clients determine whether the insurer has complied with California law or whether its conduct may constitute insurance bad faith.

As obesity treatment continues to evolve, health plans must evolve with it. Patients should not be denied access to medically necessary care simply because insurers are slow to recognize advances in modern medicine. If you believe your insurance claim or request for coverage has been wrongfully denied, contact Gianelli & Morris for a no-cost case evaluation.